Abstract:Objective To analyze the clinical characteristics of patients with hydrocephalus secondary to cobalamin C (cblC) deficiency and to discuss the optimal strategies for assessing and treating such patients by performing clinical and laboratory studies in 70 patients. Methods A total of 1,211 patients were clinically diagnosed with methylmalonic acidemia (MMA) from 1998 to 2019. Among them, cblC deficiency was confirmed in 70 patients with hydrocephalus by brain imaging and biochemical and genetic analysis. Results Of the 70 patients, 67 (95.7%) had early-onset MMA and homocystinuria. The patients typically had high blood propionylcarnitine and total homocysteine, low methionine, and methylmalonic aciduria. Signs of intracranial hypertension were relatively rare. We measured ventricular dilatation early in the disease by cranial ultrasound and MRI and/or CT. Eighteen different MMACHC mutations, including 4 novel mutations (c.427C>T, c.568insT, c.599G>A, and c.615C>A), were identified biallelically in all 70 patients. c.609G>A was the most frequent mutation, followed by c.658_660del, c.217C>T, and c.567dupT. Three cases were diagnosed by postmortem study. Metabolic therapy, including cobalamin injections supplemented with oral l-carnitine and betaine, was administered in the remaining 67 cases. A ventriculoperitoneal shunt was performed in 36 cases. During the follow-up, psychomotor development, nystagmus, impaired vision, and sunset eyes improved gradually. Conclusion Hydrocephalus is a severe condition with several different causes. In this study, ventriculomegaly was found in 70 patients with cblC deficiency. Early diagnosis, etiologic treatment, and prompt surgical intervention are crucial to improve the prognosis of patients.

What problem does this paper attempt to address?

The paper attempts to address the issue of analyzing the clinical features of patients with hydrocephalus caused by cobalamin C (cblC) deficiency and discussing the best strategies for evaluating and treating such patients. Specifically, the researchers conducted a detailed analysis of 70 patients with hydrocephalus due to cblC deficiency through clinical and laboratory studies, aiming to explore the importance of early diagnosis, etiological treatment, and timely surgical intervention in improving patient prognosis. ### Main Issues: 1. **Clinical Features**: The researchers aim to understand the clinical manifestations of these patients, including neurodevelopmental delay, visual impairment, epilepsy, etc. 2. **Metabolic Abnormalities**: Analyze the metabolic products in the blood and urine of patients, such as propionylcarnitine, total homocysteine, methionine, and methylmalonic acid, to confirm the diagnosis of cblC deficiency. 3. **Gene Mutations**: Detect the MMACHC gene mutations in patients to identify known and novel mutations. 4. **Treatment Strategies**: Evaluate the effects of metabolic treatments (such as cobalamin injections, L-carnitine, and betaine supplementation) and surgical treatments (such as ventriculoperitoneal shunt) to explore the best treatment options. 5. **Prognosis Assessment**: Follow up to observe the improvement of patients' symptoms, especially changes in psychomotor development, nystagmus, visual impairment, and sunset eye. ### Research Background: - **Methylmalonic Acidemia (MMA)**: This is a common organic aciduria mainly caused by enzyme defects or metabolic defects of the cofactor adenosylcobalamin. - **cblC Deficiency**: This is a subtype of MMA, often accompanied by hyperhomocysteinemia, which can lead to severe neurological damage, including hydrocephalus. - **Hydrocephalus**: This is a serious complication that requires timely diagnosis and treatment; otherwise, it will affect the patient's prognosis. ### Research Methods: - **Patient Selection**: From 1998 to 2019, a total of 1211 MMA patients were diagnosed, of which 70 were confirmed to have cblC deficiency with hydrocephalus. - **Biochemical Testing**: Analyze the metabolic products in blood and urine through liquid chromatography-tandem mass spectrometry and gas chromatography-mass spectrometry. - **Gene Analysis**: Detect MMACHC gene mutations through Sanger sequencing and next-generation sequencing technologies. - **Imaging Examination**: Assess the degree of hydrocephalus through CT and MRI. - **Treatment Plan**: Include metabolic treatment and surgical treatment, and conduct follow-up observations. ### Conclusion: - **Early Diagnosis and Treatment**: Early diagnosis and metabolic treatment can reduce the occurrence and development of hydrocephalus. - **Surgical Intervention**: For patients with severe hydrocephalus, timely ventriculoperitoneal shunt can significantly improve symptoms and prognosis. - **Gene Mutations**: 18 MMACHC gene mutations were found in 70 patients, 4 of which were newly discovered mutations. Through these studies, the authors hope to raise awareness of cblC deficiency and its complications, providing better diagnostic and treatment recommendations for clinicians.

Analysis of 70 patients with hydrocephalus due to cobalamin C deficiency